BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28128193)

  • 1. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].
    Yang X; Xue L; Guo L; Wen P; Lin D
    Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):243-53. PubMed ID: 24667263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.
    Lee JG; Kim S; Shim HS
    Lung Cancer; 2012 Jul; 77(1):156-61. PubMed ID: 22418245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDX-2 Expression in Primary Lung Adenocarcinoma.
    Cowan ML; Li QK; Illei PB
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
    Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
    Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
    Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
    Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
    Lin CS; Liu TC; Lai JC; Yang SF; Tsao TC
    Int J Med Sci; 2017; 14(13):1410-1417. PubMed ID: 29200955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
    Ke HG; Zhou XY; Shen Y; You QS; Yan Y; Shen ZY
    Oncol Res; 2012; 20(5-6):221-9. PubMed ID: 23581229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
    El Hag M; Schmidt L; Roh M; Michael CW
    Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry Profile Predicts
    Li W; Niehaus AG; O'Neill SS
    Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
    Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
    Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
    Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
    Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Characteristics of Napsin A, TTF 1 and EGFR Mutation Expression in Mucinous Lung Cell Carcinomas.
    Genova SN; Belovezhdov VT; Bichev SN; Danev VH
    Folia Med (Plovdiv); 2017 Jun; 59(2):174-182. PubMed ID: 28704186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.
    Zhang Z; Ye S; Zhang M; Wu J; Yan H; Li X; He J
    Tumour Biol; 2017 Jul; 39(7):1010428317720212. PubMed ID: 28720066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.